NPM1 and acute myeloid leukemia: While these data indicated that NPM1-mutated AML cases might be an AML subgroup that responds to BV6 treatment, additional markers may be necessary to prospectively define sensitive AML cases, as IDH mutations have been reported to confer adverse prognosis in AML with NPM1 mutations [52].